Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 9;14(12):4077.
doi: 10.3390/jcm14124077.

Time-to-Event Modeling for Survival Prediction of Osimertinib as the First- and Second-Line Therapy

Sungjae Lee  1   2 , Heungjo Kim  1   2 , Hongjae Lee  1   2 , Jongsung Hahn  3 , Min Jung Chang  1   2   4
Affiliations
Review

Time-to-Event Modeling for Survival Prediction of Osimertinib as the First- and Second-Line Therapy

Sungjae Lee et al. J Clin Med. .

Abstract

Objectives: To predict the survival rates of Osimertinib as first- and second-line therapy using time-to-event models based on literature data. Methods: Kaplan-Meier curves from randomized clinical trials were extracted after a systematic search of PubMed and Cochrane Library from their inception to 10 May 2023. Randomized clinical trials of Osimertinib reporting both first- and second-line overall survival (OS) and progression-free survival (PFS) in NSCLC patients with specific mutations, compared to earlier epidermal growth factor receptor (EGFR) inhibitors and chemotherapy. Kaplan-Meier curves of OS and PFS were extracted from published articles. A two-column raw dataset (time, survival probability) was extracted, and time-to-event outcomes (time, event) were derived using a graphic reconstructive algorithm. Data analysis was conducted from 1 June 2023 to 31 January 2024. Primary outcomes included OS and PFS for time-to-event modeling of Osimertinib as first- and second-line therapy. Results: The Weibull model, incorporating race as a covariate, best fit the first-line OS data. The log-logistic model best fit first-line PFS and second-line OS/PFS data. Based on these models, the predicted median OS for first-line and second-line treatment were 36.35 months (95% CI, 33.53-39.30 months) and 27.46 months (95% CI, 25.30-29.99 months), respectively. The predicted median PFS were 18.11 months (95% CI, 16.37-19.90 months) and 10.35 months (95% CI, 9.31-11.44 months), respectively. The predicted 3- and 5-year survival rates with first-line Osimertinib were 51% and 23%, respectively. Subgroup analysis revealed longer estimated 3- and 5-year survival rates for non-Asian patients compared to Asian patients (60% vs. 49% and 29% vs. 21%, respectively). Conclusions: The predicted survival rates from the time-to-event modeling align with the original clinical trial results, and an ethnic difference in Osimertinib efficacy was observed.

Keywords: Osimertinib; non-small cell lung cancer (NSCLC); time-to-event modeling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The simulation survival curves for final OS models as the first-line treatment (a) and second-line treatment (b), respectively.
Figure 2
Figure 2
The simulation survival curves for final PFS models as the first-line treatment (a) and second-line treatment (b), respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N. Engl. J. Med. 2002;346:92–98. doi: 10.1056/NEJMoa011954. - DOI - PubMed
    1. Zhou C., Wu Y., Chen G., Feng J., Liu X.-Q., Wang C., Zhang S., Wang J., Zhou S., Ren S. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Ann. Oncol. 2015;26:1877–1883. doi: 10.1093/annonc/mdv276. - DOI - PubMed
    1. Fukuoka M., Wu Y.-L., Thongprasert S., Sunpaweravong P., Leong S.-S., Sriuranpong V., Chao T.-Y., Nakagawa K., Chu D.-T., Saijo N. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS) J. Clin. Oncol. 2011;29:2866–2874. doi: 10.1200/JCO.2010.33.4235. - DOI - PubMed

LinkOut - more resources